跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 30 条关于
“MyD88”
全部
30
临床试验
10
药物
1
机构
0
资讯
19
2年前
Sanofi's KT-474 Shows Promise as First-in-Class MyD88 Inhibitor for Inflammatory Diseases
去年
SPIMA Therapeutics Launches with Exclusive License for Myddosome Inhibitor SPM001
去年
Breakthrough Developments in Waldenström Macroglobulinemia Treatment: BTK Inhibitors and Novel Therapies Show Promise
去年
Iopofosine I 131 Shows Promise in Heavily Pretreated Waldenström Macroglobulinemia
去年
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in Waldenstrom's Macroglobulinemia
去年
NX-5948 Demonstrates Promising Activity in Relapsed/Refractory Waldenström Macroglobulinemia
去年
Kymera's STAT3 Degrader KT-333 Shows Promise Across Multiple Lymphomas and Solid Tumors
去年
SPIMA Therapeutics Launches with Focus on Peptide-Based Immunotherapies for Unmet Needs
去年
Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
去年
BeiGene's BRUKINSA Approved by Swissmedic for Waldenström’s Macroglobulinemia Treatment
第 1 页,共 2 页
上一页
下一页